HTFL stock forecast, quote, news & analysis
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease... Show more
Why HeartFlow (HTFL) Stock Is Up +91% in the Last 30 Days
Key Takeaways
- HeartFlow shares rose roughly 91% over the trailing 30 days, from about $25.59 to $48.94, following a strong second-quarter 2026 earnings report and an upgraded full-year outlook.
- Second-quarter revenue climbed 48% year over year to $64.1 million, with U.S. revenue up 51%, driven by its AI-based coronary artery disease diagnostics.
- Management raised full-year 2026 revenue guidance to $246 million–$250 million and lifted its non-GAAP gross-margin outlook to about 82%.
- Several Wall Street firms raised price targets after the results, though the company remains unprofitable on a GAAP basis.
- Over the last quarter, shares have gained roughly 67%, extending a sharp multi-month re-rating.
HeartFlow (HTFL) Company Overview and Market Position
HeartFlow, Inc. is a commercial-stage medical technology company headquartered in San Francisco that uses artificial intelligence and advanced computational modeling to diagnose and manage coronary artery disease without invasive procedures. Its platform converts coronary CT angiography images into personalized, three-dimensional models of the coronary arteries, helping clinicians assess blood flow and plaque burden.
The company's product suite includes FFRCT Analysis, Plaque Analysis, RoadMap Analysis, PCI Navigator, and the recently launched Plaque Staging tool. HeartFlow went public in August 2025 and operates primarily in the United States, with additional presence in Europe and other international markets. Investors follow the stock for its rapid revenue growth, expanding gross margins, and positioning within the under-penetrated cardiac CT market.
HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HeartFlow shares advanced approximately 91%, climbing from a closing price of $25.59 on July 28, 2026, to $48.94 by August 26, 2026. The bulk of the move occurred on August 14, when the stock gapped sharply higher and closed up roughly 36% following second-quarter results and raised guidance, before continuing to climb into the $50 range later in the month.
The quarterly picture tells a similar, though slightly more measured, story. From a close of about $29.28 in late May 2026, the stock rose roughly 67% over the following three months. Much of that gain reflects a re-rating concentrated in August, after shares had traded in a choppy range and briefly dipped into the low-to-mid $24 area in mid-July.
What Drove HTFL Stock Price in the Last 30 Days
The primary catalyst was HeartFlow's second-quarter 2026 earnings report, released on August 13, 2026. The company posted revenue of $64.1 million, up 48% year over year and ahead of consensus, with U.S. revenue rising 51% to $59.6 million. Non-GAAP gross margin expanded to 83.3% from 75.6% a year earlier, and the adjusted loss per share of $0.07 came in well ahead of analyst expectations.
Management also raised its full-year 2026 revenue guidance to $246 million–$250 million, implying 40%–42% growth and up from a prior range of $228 million–$232 million. The company lifted its plaque revenue outlook to $29 million–$31 million and its non-GAAP gross-margin guidance to about 82%, citing momentum in its Plaque Analysis offering, durable FFRCT utilization, and AI-driven operating efficiency. In response, analysts including Stifel, JPMorgan, Wells Fargo, and Piper Sandler raised price targets or reiterated constructive ratings.
What Drove HTFL Stock Performance Over the Last Quarter
The quarterly advance reflects a broader re-rating of HeartFlow as a growth story built on accelerating adoption of its AI diagnostic platform. Before the August earnings catalyst, shares had traded roughly sideways to lower, weighed down by concerns about profitability and a competitive cardiac diagnostics landscape. The second-quarter report shifted that narrative by demonstrating faster revenue growth, expanding gross margins, and improved operating leverage.
Broader tailwinds also supported the move, including continued expansion of the coronary CT angiography market, growing interest in non-invasive cardiac testing, and institutional accumulation. Management noted rising hedge fund and institutional participation, alongside confidence in reaching cash-flow profitability by mid-2028 and a balance sheet holding $246.8 million in cash and investments.
Trending AI Robots
For traders seeking a data-driven approach to market opportunities, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this section, giving users a focused view of strategies currently generating momentum. The featured bots vary in strategy, timeframe, and performance metrics, so investors can explore approaches that align with their own objectives. Whether you follow established names or emerging movers, the page offers a way to monitor how algorithmic strategies are positioned across the market.
HTFL Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching whether HeartFlow can sustain its Plaque Analysis momentum and FFRCT utilization into the second half of 2026, along with continued progress toward its raised revenue and gross-margin targets. Upcoming clinical milestones, including the launch of new studies in high-risk asymptomatic populations, could expand the company's addressable market and influence the long-term growth narrative. Reimbursement policy, particularly evolving CMS treatment of AI-enabled diagnostic software, and competitive dynamics in cardiac CT diagnostics remain important variables. Because the company is not yet profitable on a GAAP basis, margin trajectory, operating leverage, and the path to cash-flow profitability by mid-2028 will also be closely scrutinized.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HTFL sees MACD Histogram crosses below signal line
HTFL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 9 instances where the indicator turned negative. In 9 of the 9 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HTFL moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 4 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 14 of 16 cases where HTFL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on HTFL as a result. In 22 of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
HTFL moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HTFL crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for HTFL moved above the 200-day moving average on August 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +5.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 63 of 70 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
HTFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 29 of 41 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.504) is normal, around the industry mean (7.171). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (44.460). HTFL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.499). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. HTFL's P/S Ratio (20.367) is slightly higher than the industry average of (5.983).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry